Immune Regulation
2011
FOUNDED
PRIVATE
STATUS
Later Stage VC
LATEST DEAL TYPE
$5.51M
LATEST DEAL AMOUNT
3
INVESTORS
Description
Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases resulting from a poorly controlled or overactive immune response. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for diseases modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis and inflammatory bowel diseases to get better treatment and faster recovery.
Website
Formerly Known As
Peptinnovate
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- Stevenage Bioscience Catalyst, Gunnels Wood Road
- Hertfordshire
- Stevenage SG1 2FX
- England, United Kingdom
+44 01438 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Immune Regulation’s full profile, request a free trial.
Immune Regulation Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 01-Jan-2018 | $5.51M | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC | 14-Jun-2017 | 00.000 | 00.00 | Completed | Generating Revenue | |
| 3. Early Stage VC | 28-Jul-2015 | 00000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 2. Grant | $938K | Completed | Generating Revenue | |||
| 1. Angel (individual) | 17-Dec-2014 | $938K | $938K | 0000 | Completed | Generating Revenue |
Immune Regulation Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 |
Immune Regulation Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| 24Haymarket | Angel Group | Minority | 000 0000 | 000000 0 | ||
| NCL Technology Ventures | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Metellus | Venture Capital | Minority | 000 0000 | 000000 0 |
Immune Regulation Executive Team (11)
2 Former Executives
You’re viewing 5 of 11 executives. Get the full list »Immune Regulation Board Members (11)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Anthony Martin Ph.D | Immune Regulation | Chairman | 000 0000 | |
| Ben Cons | Immune Regulation | Board Member | 000 0000 | |
| Christopher Smith | Immune Regulation | Board Member | 000 0000 | |
| Clive Page | Immune Regulation | Chairman | 000 0000 | |
| David Beadle | Immune Regulation | Chief Business Officer & Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 11 board members. Get the full list »